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Aim of the database: The Danish Head and Neck Cancer database is a nationwide clinical 
quality database that contains prospective data collected since the early 1960s. The overall aim 
of this study was to describe the outcome of the national strategy for multidisciplinary treatment 
of head and neck cancer in Denmark and to create a basis for clinical trials.
Study population: The study population consisted of all Danish patients referred for treatment 
of squamous cell carcinoma of the larynx, pharynx, oral cavity, or neck nodes from unknown 
primary or any histopathological type (except lymphoma) of cancer in the nasal sinuses, salivary 
glands, or thyroid gland (corresponding to the International Classification of Diseases, tenth 
revision, classifications C.01–C.11, C.30–C.32, C.73, and C.80).
Main variables: The main variables used in the study were symptoms and the duration of the 
symptoms; etiological factors; pretreatment and diagnostic evaluation, including tumor–node–
metastasis classification, imaging, histopathology, and laboratory tests; primary treatment with 
semidetailed information of radiotherapy, surgery, and medical treatment; follow-up registration 
of tumor status and side effects; registration of relapse and treatment thereof; and registration 
of death and cause of death.
Main results: Data from .33,000 patients have been recorded during a period of .45 years. 
In this period, the outcome of treatment improved substantially, partly due to better treatment 
as a result of a series of continuous clinical trials and subsequent implementation in national 
guidelines. The database has furthermore been used to describe the effect of reduced waiting 
time, changed epidemiology, and influence of comorbidity and socioeconomic parameters.
Conclusion: Half a century of registration of head and neck cancer treatment and outcome has 
created the basis for understanding and has substantially contributed to improve the treatment 
of head and neck cancer at both national and international levels.
Keywords: head and neck cancer, squamous cell carcinoma, radiotherapy, national population 
cohort
About the Danish Head and Neck Cancer group
The Danish Head and Neck Cancer (DAHANCA) group was established in 1976 as a 
working group by the Danish Society for Head and Neck Oncology with the  primary 
aim to develop national guidelines for the treatment of head and neck cancer in 
 Denmark. DAHANCA group’s activities have included creating and running a national 
database, development of treatment guidelines, performing numerous national clinical 
protocol studies (.30), and providing quality assurance programs. The group is multi-
disciplinary and consists of representatives from all the oncology centers in Denmark 
treating head and neck cancer, including oncologists, otolaryngologists, pathologists, 
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imaging diagnosticians, experimental researchers, epidemi-
ologists, and other expert support, eg, medical physicists. 
The DAHANCA model was behind the establishment of 
the structure of the Danish Multi disciplinary Cancer Groups 
(DMCG), and the DAHANCA group is thus the oldest of 
the still active DMCG.
There are ∼1,400 new cases of head and neck cancer 
every year. Traditionally, these include cancer of the larynx, 
pharynx, oral cavity, sinuses, salivary glands, thyroid glands, 
and neck nodes from unknown primary type of cancer (cor-
responding to the International Classification of Diseases, 
tenth revision, classifications C.01–C.11, C.30–C.32, C.73, 
and C.80), but did not include cancer of the lip. The most 
significant types are cancer of the pharynx, larynx, and oral 
cavity. Almost all of these are squamous cell carcinomas, 
which etiologically are strongly linked to tobacco and alco-
hol use and increasingly also to infections with especially 
human papilloma virus, since human papilloma virus-related 
oropharyngeal cancer has become the most rapidly increas-
ing cancer type in Denmark. The disease is characterized as 
being locoregional with late and infrequent occurring distant 
metastases. The therapeutic strategy is therefore aimed toward 
eradicating the disease at the site of the primary tumor and the 
regional lymph nodes. Such a treatment is typically surgery or 
radiotherapy, and over the past years in Denmark, focus has 
deliberately been on radiotherapy as the primary modality, as 
this ensures the best possibility of organ conservation.
DAHANCA group has been an active and well-established 
structure for 40 years and has provided a solid foundation for 
the treatment of head and neck cancer in Denmark and has 
become recognized internationally as one of the major head 
and neck cancer groups. In this aspect, it should be noted 
that the treatment of head and neck cancer in Denmark has 
rather a good outcome seen with international eyes.
DAHANCA database
The registration of patients with head and neck cancer is 
the essential backbone of the DAHANCA structure, and the 
associated database includes currently .33,000 patients, with 
an annual increase of 1,400 patients (Table 1).
Historically, the database started as a local home-designed 
database at the Department of Oncology, Aarhus University 
Hospital, Aarhus, Denmark, where the medical physicist 
Mogens Hjelm Hansen in the early 1970s created an elaborate 
program for the registration of head and neck cancer (the 
radiation physics department was among the first places where 
computers were introduced in health care). This program later 
formed the basis for equivalent databases in Copenhagen 
and Odense and a subsequent retrospectively registration 
of, especially, laryngeal cancer back to the early 1960s. The 
registration of cases later expanded to include the new oncology 
centers in Aalborg and Herlev, and a full national registration 
of larynx cancer has taken place since 1971. In the same time 
period, there have also been regional and more sporadic registra-
tions of pharynx and oral cavity cancers. At a national level, the 
three initial databases included all patients with larynx cancer 
between 1971 and 1991.
In connection with a large clinical trial,1 the national 
database was reconstructed and expanded to include all can-
cers of the larynx, pharynx, and oral cavity. Each of the five 
oncology centers had their own databases (named DA 1–5), 
which were all copies of a central master. Thus, data were 
gathered locally and were immediately available for daily use 
and research purposes at the individual institutions. The DA 
1–5 data files were regularly merged into the joint database 
at the secretariat in Aarhus and thus formed the national 
DAHANCA clinical database. The structure was based on the 
“MedLog” program. Also, the initial three databases named 
(AKH, HLM, and HL3) were merged and restructured using 
the same program. The registration in DA 1–5 covered the 
period 1992–1999. In 1995, a special DATHYRCA database 
for registering thyroid cancer2 and more lately databases for 
unknown primary neck tumor,3 salivary gland tumor,4 and 
sinonasal cancer were established.5
In 2000, the DAHANCA database was changed into a 
central web-based database (OCX), which allowed interactive 
registration directly on a central server with the immediate 
possibility for quality checks of the data and with instant 
correction of errors. This increased the quality assurance and 
gave direct access to information about the current status of 
the patients. The OCX database is based on the development 
tool Clarion and uses Hypertext Transfer Protocol Secure 
certificate with an Hypertext Transfer Protocol Secure con-
nection; all communications are securely encrypted. All 
users’ logins are logged and registered. The operating system 
is on a Windows Server 2012 platform, and the server is situ-
ated at Aarhus University. The system is flexible and can be 
modified in connection with specific protocols and projects. 
All projects are carried out in accordance with the applicable 
legislation and regulations, including the European Union’s 
Clinical Trials Directive, and corresponding regulations for 
the use of good clinical practice and quality assurance, and 
the database fulfills the Danish Data Protection Agency’s 
description of standard specification and requirements for 
security. The OCX database has been active since 2000, and 
the structure has formed the basis for several other clinical 
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quality cancer databases (eg, melanoma, sarcoma, ocular 
cancer, childhood cancer databases). Moreover, in 2011, 
the DAHANCA database was transformed from being a 
“private” research database to a clinical quality database in 
public auspices under the Danish Clinical Registries (RKKP), 
while still allowing the continued use for research purposes. 
This simplified the correlation with other public databases, 
such as the Danish Cancer Registry (DCR), and allowed the 
database to be used as an indicator of quality.
Structure of the database
Approximately 33,000 patients are included in the database, 
which has ∼300 basic variables.6,7 Additionally, there is the 
possibility of specially registered parameters in connection 
with specific projects. The aim is that established variables 
remain in the database, and to have, to a large extent, 
continuous variables that remain unchanged. International 
standardized classifications are used in this context where 
such classifications exist (eg, Union for International Cancer 
Control tumor–node–metastasis classification). With regard 
to side effects, international principles are also applied, but 
the principles that we initially developed have now been 
adopted by other organizations, and thus, the DAHANCA 
database has contributed to the international standard with 
regard to registration of side effects from radiotherapy. As 
not all variables are in use at any time, the daily registration 
probably involves 100–150 different parameters.
The basic registration includes the following (refer forms 
at www.dahanca.dk):
1. On study: symptoms and the duration of the symptoms, 
etiological factors, pretreatment and diagnostic evalu-
ation, including tumor–node–metastasis classification, 
imaging, histopathology, and laboratory tests,
2. Primary treatment: semi-detailed information of 
radiotherapy, surgery, and medical treatment.
3. Follow-up: registration of vital and tumor status and acute 
and late side effects.
4. Recurrence: registration of relapse and treatment 
thereof.
5. Death form: registration of death and cause of death.
Besides comparison with the DCR, vital status is checked 
regularly through updates from the civil registration number 
register. In certain situations, there have been correlations 
with specific extracts from the National Patient Discharge 
Registry and the Cause of Death Register.
How do we register data?
The principle of the DAHANCA database has throughout 
the years been a uniform structure of data description and 
a local registration. For the first many years, no actual 
clinical record forms existed, but the patient’s journal was 
considered to be the paper-related data documentation and 
was used as a basis for data entry. For practical reasons, 
paper registration forms have been used since 1991 (refer 
forms at www.dahanca.dk). The gathering and recording 
of data has always been done by a few knowledgeable 
people, mainly senior specialist doctors. Owing to the 
limited amount of such people, who have been involved 
over many years and who know the problems in detail, both 
communication and collection of data are done in a very 
uncomplicated and pragmatic fashion. This dependency 
on a few highly specialized persons is both the strength 
and weakness of the database, because it not only gives 
it extremely high quality but also makes it vulnerable to 
changes. The database has a number of error indicators 
built in, which safeguards against logical errors and at the 
same time has the option of reminders if information is 
missing. Furthermore, lists of irregularities are instantly 
produced in a continuous attempt to collect missing data 
or correct any errors.
Table 1 Number of patients included in the DAHANCA database as a function of time period and tumor site
Tumor site Time period and database acronym All included
Pre 1971  
(AKH, HLM, HL3)
1971–1991  
(AKH, HLM, HL3)
1992–1999  
(DA 1–5)
2000–2015 
(OCX)
Larynx 857 4,092 2,018 3,694 10,661 (9,804)
Pharynx 254 2,197 1,756 6,304 10,511 (8,060)
Oral cavity 1,697 3,867 5,664 (5,664)
Sino-nasal 114 276 512 902 (512)
Salivary glands 189 661 643 1,493 (1,304)
Thyroid 652 3,692 4,344 (4,344)
Unknown primary 293 293 (293)
All 1,225 6,754 6,784 19,005 33,768 (29,881)
Note: Numbers in bold indicate the time periods with full national coverage of patient cohorts.
Abbreviation: DAHANCA, Danish Head and Neck Cancer.
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Quality assurance and correlation 
with other registers
The database is verified through the numerous related 
research projects.6,7 Simultaneously, a specific comparison 
to the DCR is performed at least annually, where all cases 
in the DCR have been sought to be verified through the 
 DAHANCA database, and in case of errors (in the DCR), 
these are explored when possible. Thus, there is currently a 
full national registration of DAHANCA database ranging 
back to 1971 (Table 1). This has shown that the DAHANCA 
database contains 99.7% of the originally known cases in the 
DCR, and an additional number of patients, currently 2%, 
have been identified, who were not in the DCR. Further-
more, a number of erroneous registrations in the DCR have 
been corrected (in the DAHANCA database). The complete 
interaction between the two databases clearly shows that, 
in principle, there exists a total nationwide coverage in the 
DAHANCA database and further ascertains that the DAH-
ANCA database has the potential of increasing the quality of 
the DCR’s data. The practical aspects of such data feedback 
to DCR are currently being explored.
This investigative high-quality work has been performed 
in great detail, and in cases of doubt, relevant additional hos-
pital records and/or other material have been obtained. Thus, 
all patients in the database have had their hospital records 
scrutinized at least once, and all updates are verified by a 
specialist doctor. With the DCR’s well-known almost complete 
coverage of cancer cases in Denmark as a starting point, it is 
our impression that with the DAHANCA database we have 
a near-perfect clinical register, which probably is the world’s 
most accurate recording of head and neck cancer treatment.
Approval of the database
The initial Aarhus-derived database was approved with regis-
ter regulations at Vejle County. Later, the national database 
was registered and approved as a research database by the 
Danish Data Protection Agency (record nos 1995-1200-282 
and 2004-41-4802). Since 2011, it has been a public clinical 
quality database (record no 1-16-02-249-14). Jens Overgaard 
is the overall data responsible head, and regionally, the respon-
sibility lies with the consultant responsible for the head and 
neck cancer treatment at the respective oncological centers.
Economy of the database
As with other research-based databases, the project has 
initially been based on “con amore” activities performed 
by interested professionals at weekends and in late hours. 
Gradually, the need for organized help has increased and 
the database has throughout the years been partly financed 
in connection with research projects, where among others, 
PhD students were assigned to the activities mainly spon-
sored through the Danish Cancer Society and the Medical 
Research Council (we have constantly tried to avoid any 
commercial influence and sponsoring). Since 2006, we have 
been partly supported thorough the DMCG/RKKP structure. 
However, the activities have throughout benefited from being 
part of the infrastructure at the Department of Experimental 
 Clinical Oncology at Aarhus University Hospital and from 
the numerous dedicated persons who have used their spare 
time to strengthen the database.
Use of the database
The value of any database is linked with its use, and the qual-
ity data are accessible through access to the RKKP (http://
www.rkkp.dk/forskningsadgang/). Throughout the years, 
the DAHANCA database has been extensively explored and 
has served as an active research database that has formed 
the basis for numerous scientific projects and publications, 
including 15 PhD and doctoral theses (for full list, refer the 
DAHANCA homepage [www.dahanca.dk]). It has been the 
supporting database for .30 prospective clinical trials and 
has acted as a baseline for large retrospective studies describ-
ing the natural history and treatment outcome in head and 
neck cancer. Examples of studies6,8–11 are given in Figure 1, 
and more can be found on the DAHANCA web site. This 
means that the database is constantly revised and updated 
and, consequently, is extremely well verified.
Since many of the DAHANCA protocols have focused 
on biological-based improvement of head and neck cancer 
treatment, these translational studies have been based on a 
large amount of clinical material.10–13 This DAHANCA-related 
biobank contains biological material (tumor, normal tissue cell 
lines, blood samples, DNA, RNA, etc) from .4,000 patients 
with detailed clinical data and follow-up. Also, paraffin- 
embedded tumor biopsies are available from almost all 
patients. Currently, we are systematically collecting material 
from new patients in the National Danish Cancer Biobank.
The database has not only been strengthened by linkage 
to other registries6,7 but has also shown its value by being 
a supportive basis for studies of comorbidity,6 value of 
follow-up,14 or socioeconomical relationship in patients with 
head and neck cancer.15,16 In the foreseen future, it will be part 
of international comparisons of treatment strategies, and for 
such purpose, a clinical database is far superior than using 
cancer registry comparisons (such as the Nordic NORDCAN 
study), since such databases are incomplete and inaccurate 
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regarding clinical information. Thus, it is important to use 
the right tools/databases for the right purposes, and when 
conclusions about therapeutic strategies are the aim, the data 
must be obtained from a well-verified clinical quality data-
base. We believe that the DAHANCA database is a prime 
example of such an activity.
Acknowledgment
This article was funded by the Danish Cancer Society and the 
Program for Clinical Research Infrastructure established by 
the Lundbeck Foundation and the Novo Nordisk Foundation 
and administered by the Danish Regions.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions 
per week of conventional radiotherapy of squamous-cell carcinoma of 
head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 
2003;362:933–940.
35
28
21
M
ed
ia
n
 “
w
ai
ti
n
g
 t
im
e”
 d
ay
s
14
7
1968 1973 1978 1983 1988 1993 1998
Time from first contact with
oncological center to first day
or radiotherapy/surgery
2003 2008 2013
Year of treatment
DAHANCA database
Larynx
Oropharynx
Denmark 1977–2013
A
L
o
co
re
g
io
n
al
 c
o
n
tr
o
l (
%
)
20
40
60
80
100
0
0 6 12 18 24 30 36 42 48 54
5 fx/wk
5 fx/wk + NIM
6 fx/wk + NIM
80%
50%
42%
26%
6 fx/wk + NIM + cis-P
Stage 3–4 larynx, hypopharynx, oropharynx
DAHANCA database
60
Time after treatment (months)
B
N
u
m
b
er
 o
f 
p
at
ie
n
ts
0
50
100
150
200
250
300
42%
37%
33%
55%
70%
*P16-positive
74%*350
400
1977 1982 1987 1992 1997 2002 2007 2012
Year
C Comorbidity and survival
O
ve
ra
ll 
su
rv
iv
al
 (
%
)
0
25
50
75
100
0 1 2 3 4 5
P<0.001
N=12,596
CCI =0 50%
Crede HR
CCI =1: HR =1.16 (1.08–1.25)
No comorbidity   9,013
Number at risk
Mild comorbidity   2,110
Moderate comorbidity   1,195
Severe comorbidity   1,237
6,286
1,582
854
799
4,843
1,198
604
549
3,943
962
473
410
3,880
723
368
291
2,831
567
286
221
CCI =2: HR =1.34 (1.22–1.46)
CCI =3: HR =1.63 (1.51–1.60)
CCI =1 45%
CCI =2 39%
CCI =3 33%
Time after treatment (years)
D
Figure 1 Examples of studies involving the DAHANCA database.
Notes: Panel (A) shows the development in waiting time between diagnosis and start of treatment. The prominent increase found in the DAHANCA database was 
the direct cause that released a massive intervention in the form of “cancer packages’” aimed to reduce the waiting time (implemented in September 2006). Panel (B) 
shows an illustration of biological modification of radiotherapy seen in a series of clinical trials in the treatment of advanced larynx and pharynx carcinoma. Conventional 
fractionated treatment with 66–68 Gy given in five weekly fractions (fx) of 2 Gy was significantly enhanced by adding the hypoxic radiosensitizer NIM to overcome hypoxic 
radioresistance. This was further improved by treating with six weekly fractions and thereby reducing the overall treatment time to compensate for radiation-induced 
accelerated repopulation of tumor stem cells. Finally the intrinsic radioresistance was targeted by adding concomitant chemotherapy with cis-P. Overall, did such strategy 
lead to a threefold improvement in treatment outcome? The validity of this DAHANCA strategy is now been explored in a large clinical trial in Europe, North America, and 
Australia. Modified from Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Cancer Rev. 2016;16:234–249.11 Panel (C) shows 
the crude incidence of laryngeal and oropharyngeal carcinomas in Denmark during 1977–2013 and its relationship with HvP/p16 positivity. Reprinted from Radiother Oncol, 95, 
Lassen P, The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome, 371–380, Copyright (2010), with permission from Elsevier.12 
Panel (D) shows the impact of Charlson Comorbidity index (CCi) on outcome of treatment in a cohort of 12,623 Danish HNSCC patients, 1992–2008. The study resulted 
in creating a specific head and neck cancer comorbidity index, now implemented in routine use. Reproduced from Bøje CR, Dalton SO, Grønborg TK, et al. The impact of 
comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol. 2013;52:285–293.6
Abbreviations: DAHANCA, Danish Head and Neck Cancer; NIM, nimorazole; cis-P, cisplatin; HVP, human papilloma virus; HNSCC, head and neck squamous cell 
carcinoma; wk, week; HR, hazard ratio.
Clinical Epidemiology 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
495
Danish Head and Neck Cancer database
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
27
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
2. Londero SC, Mathiesen JS, Krogdahl A, et al. Completeness and valid-
ity in a national clinical thyroid cancer database: DATHYRCA. Cancer 
Epidemiol. 2014;38:633–637.
3. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. 
Cervical lymph node metastases from unknown primary tumours. 
Results from a national survey by the Danish Society for Head and Neck 
 Oncology. Radiother Oncol. 2000;55:121–129.
4. Bjørndal K, Krogdahl A, Therkildsen MH, et al. Salivary gland  carcinoma 
in Denmark 1990–2005: a national study of incidence, site and histology. 
Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral 
Oncol. 2011;47:677–682.
5. Thorup C, Sebbesen L, Danø H, et al. Carcinoma of the nasal 
 cavity and paranasal sinuses in Denmark 1995–2004. Acta Oncol. 
2010;49:389–394.
6. Bøje CR, Dalton SO, Grønborg TK, et al. The impact of comorbid-
ity on outcome in 12 623 Danish head and neck cancer patients: a 
population based study from the DAHANCA database. Acta Oncol. 
2013;52:285–293.
7. Lyhne NM, Johansen J, Kristensen CA, et al. Incidence of and survival 
after glottic squamous cell carcinoma in Denmark from 1971 to 2011 – 
a report from the DAHANCA group. Eur J Cancer. 2016;59:46–56.
8. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in  waiting 
time for radiotherapy in head and neck cancer. Radiother Oncol. 
2007;84:5–10.
9. Lyhne NM, Christensen A, Alanin MC, et al. Waiting times for diagnosis 
and treatment of head and neck cancer in Denmark in 2010 compared to 
1992 and 2002. Eur J Cancer. 2013;49:1627–1633.
 10. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, 
 Overgaard J. Effect of HPV-associated p16INK4A expression on 
response to radiotherapy and survival in squamous cell carcinoma of 
the head and neck. J Clin Oncol. 2009;27:1992–1998.
 11. Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the 
era of precision medicine. Nat Cancer Rev. 2016;16:234–249.
 12. Lassen P. The role of human papillomavirus in head and neck 
 cancer and the impact on radiotherapy outcome. Radiother Oncol. 
2010;95:371–380.
 13. Toustrup K, Sørensen BS, Nordsmark M, et al. Development of a 
hypoxia gene expression classifier with predictive impact for hypoxic 
modification of radiotherapy in head and neck cancer. Cancer Res. 
2011;71:5923–5931.
 14. Pagh A, Vedtofte T, Lynggaard CD, et al. The value of routine follow-
up after treatment for head and neck cancer. A national survey from 
 DAHANCA. Acta Oncol. 2013;52:277–284.
 15. Kjær T, Bøje CR, Olsen MH, et al. Affiliation to the work market after 
curative treatment of head-and-neck cancer: a population-based study 
from the DAHANCA database. Acta Oncol. 2013;52:430–439.
 16. Olsen MH, Bøje CR, Kjær TK, et al. Socioeconomic position and 
stage at diagnosis of head and neck cancer – a nationwide study from 
DAHANCA. Acta Oncol. 2015;54:759–766.
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk & safety of medical interventions, epidemiol-
ogy & biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies & economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
496
Overgaard et al
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
27
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
